Log in

NASDAQ:PRAH - PRA Health Sciences Stock Price, Forecast & News

$78.51
-1.36 (-1.70 %)
(As of 03/29/2020 01:42 PM ET)
Today's Range
$74.25
Now: $78.51
$80.92
50-Day Range
$64.14
MA: $94.29
$111.53
52-Week Range
$58.67
Now: $78.51
$113.10
Volume476,062 shs
Average Volume647,319 shs
Market Capitalization$4.99 billion
P/E Ratio21.28
Dividend YieldN/A
Beta1.11
PRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services. It also provides strategic solutions, such as embedded, functional services provider, staff augmentation, and custom-built development solutions, as well as commercialization services; and early development services for Phase I and Phase IIa studies, and bioanalytical analysis. The Data Solutions segment offers data, analytics, technology, and consulting solutions to the life sciences market. Its services include market intelligence services, such as targeting and compensation, and pharmaceutical audit suite services; consulting and services comprising brand analytics, managed markets, commercial effectiveness, and scientific studies/clinical hubs; and technology-enabled products and services. PRA Health Sciences, Inc. conducts clinical trials in the areas of pharmaceutical development, including oncology, immunology, central nervous system, inflammation, respiratory, cardio metabolic, and infectious diseases. The company was formerly known as PRA Global Holdings, Inc. and changed its name to PRA Health Sciences, Inc. in July 2014. PRA Health Sciences, Inc. was founded in 1976 and is headquartered in Raleigh, North Carolina.
Read More
PRA Health Sciences logo

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PRAH
CUSIPN/A
Phone919-786-8200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.07 billion
Cash Flow$6.83 per share
Book Value$17.23 per share

Profitability

Net Income$243.02 million

Miscellaneous

Employees17,500
Market Cap$4.99 billion
Next Earnings Date5/6/2020 (Estimated)
OptionableOptionable

Receive PRAH News and Ratings via Email

Sign-up to receive the latest news and ratings for PRAH and its competitors with MarketBeat's FREE daily newsletter.


PRA Health Sciences (NASDAQ:PRAH) Frequently Asked Questions

How has PRA Health Sciences' stock been impacted by COVID-19 (Coronavirus)?

PRA Health Sciences' stock was trading at $88.68 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, PRAH shares have decreased by 11.5% and is now trading at $78.51. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of PRA Health Sciences?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PRA Health Sciences in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for PRA Health Sciences.

When is PRA Health Sciences' next earnings date?

PRA Health Sciences is scheduled to release its next quarterly earnings announcement on Wednesday, May 6th 2020. View our earnings forecast for PRA Health Sciences.

How were PRA Health Sciences' earnings last quarter?

PRA Health Sciences Inc (NASDAQ:PRAH) announced its quarterly earnings results on Thursday, February, 20th. The medical research company reported $1.54 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.32 by $0.22. The medical research company earned $800.24 million during the quarter, compared to the consensus estimate of $794.91 million. PRA Health Sciences had a net margin of 7.93% and a return on equity of 28.52%. The firm's quarterly revenue was up 9.7% compared to the same quarter last year. During the same period in the previous year, the company earned $1.31 earnings per share. View PRA Health Sciences' earnings history.

What guidance has PRA Health Sciences issued on next quarter's earnings?

PRA Health Sciences updated its FY20 earnings guidance on Thursday, February, 20th. The company provided earnings per share guidance of $5.77-5.97 for the period, compared to the Thomson Reuters consensus estimate of $5.81. The company issued revenue guidance of $3.23-3.36 billion, compared to the consensus revenue estimate of $3.32 billion.

What price target have analysts set for PRAH?

9 analysts have issued 1 year price targets for PRA Health Sciences' shares. Their forecasts range from $89.00 to $128.00. On average, they anticipate PRA Health Sciences' share price to reach $110.38 in the next twelve months. This suggests a possible upside of 40.6% from the stock's current price. View analysts' price targets for PRA Health Sciences.

Has PRA Health Sciences been receiving favorable news coverage?

News headlines about PRAH stock have trended extremely negative on Sunday, according to InfoTrie. The research group ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. PRA Health Sciences earned a media sentiment score of -4.0 on InfoTrie's scale. They also assigned headlines about the medical research company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutPRA Health Sciences.

Are investors shorting PRA Health Sciences?

PRA Health Sciences saw a decline in short interest in the month of February. As of February 28th, there was short interest totaling 1,910,000 shares, a decline of 14.7% from the February 13th total of 2,240,000 shares. Based on an average daily trading volume, of 521,200 shares, the days-to-cover ratio is currently 3.7 days. Currently, 3.3% of the shares of the stock are sold short. View PRA Health Sciences' Current Options Chain.

Who are some of PRA Health Sciences' key competitors?

What other stocks do shareholders of PRA Health Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PRA Health Sciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Adobe (ADBE), Paypal (PYPL), Applied Materials (AMAT), Veeva Systems (VEEV), Lam Research (LRCX), Walt Disney (DIS), Netflix (NFLX) and Broadcom (AVGO).

Who are PRA Health Sciences' key executives?

PRA Health Sciences' management team includes the following people:
  • Mr. Colin Shannon, Chairman, CEO & Pres (Age 60)
  • Mr. Michael J. Bonello, Exec. VP, CFO & Corp. Sec. (Age 49)
  • Mr. Kent Thoelke, Exec. VP & Chief Scientific Officer
  • Mr. Thomas Byrne, VP of Legal Affairs
  • Christine Rogers, Director of PR & Corp. Communications

When did PRA Health Sciences IPO?

(PRAH) raised $306 million in an initial public offering on Thursday, November 13th 2014. The company issued 17,000,000 shares at $18.00 per share. Jefferies, Citigroup, KKR, UBS Investment Bank, Credit Suisse and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers.

What is PRA Health Sciences' stock symbol?

PRA Health Sciences trades on the NASDAQ under the ticker symbol "PRAH."

Who are PRA Health Sciences' major shareholders?

PRA Health Sciences' stock is owned by many different institutional and retail investors. Top institutional investors include Capital Research Global Investors (4.07%), Janus Henderson Group PLC (3.10%), Massachusetts Financial Services Co. MA (2.70%), State Street Corp (2.27%), Pendal Group Ltd (1.52%) and Standard Life Aberdeen plc (1.23%). Company insiders that own PRA Health Sciences stock include Fund Holdings LP Kkr and Pra Investors LP Kkr. View institutional ownership trends for PRA Health Sciences.

Which institutional investors are selling PRA Health Sciences stock?

PRAH stock was sold by a variety of institutional investors in the last quarter, including Standard Life Aberdeen plc, Bank of New York Mellon Corp, AQR Capital Management LLC, Pictet Asset Management Ltd., Capital Research Global Investors, Artemis Investment Management LLP, Acadian Asset Management LLC, and Strs Ohio. View insider buying and selling activity for PRA Health Sciences.

Which institutional investors are buying PRA Health Sciences stock?

PRAH stock was bought by a variety of institutional investors in the last quarter, including Massachusetts Financial Services Co. MA, Norges Bank, Janus Henderson Group PLC, Captrust Financial Advisors, FMR LLC, Goldman Sachs Group Inc., Mackay Shields LLC, and Assenagon Asset Management S.A.. View insider buying and selling activity for PRA Health Sciences.

How do I buy shares of PRA Health Sciences?

Shares of PRAH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is PRA Health Sciences' stock price today?

One share of PRAH stock can currently be purchased for approximately $78.51.

How big of a company is PRA Health Sciences?

PRA Health Sciences has a market capitalization of $4.99 billion and generates $3.07 billion in revenue each year. The medical research company earns $243.02 million in net income (profit) each year or $4.80 on an earnings per share basis. PRA Health Sciences employs 17,500 workers across the globe. View additional information about PRA Health Sciences.

What is PRA Health Sciences' official website?

The official website for PRA Health Sciences is http://www.prahs.com/.

How can I contact PRA Health Sciences?

PRA Health Sciences' mailing address is 4130 PARKLAKE AVENUE SUITE 400, RALEIGH NC, 27612. The medical research company can be reached via phone at 919-786-8200 or via email at [email protected]


MarketBeat Community Rating for PRA Health Sciences (NASDAQ PRAH)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  355 (Vote Outperform)
Underperform Votes:  323 (Vote Underperform)
Total Votes:  678
MarketBeat's community ratings are surveys of what our community members think about PRA Health Sciences and other stocks. Vote "Outperform" if you believe PRAH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRAH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/29/2020 by MarketBeat.com Staff

Featured Article: Insider Trading

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel